Browsing Faculty of Health Sciences by Subject "Inhibition"
Now showing items 1-10 of 39
-
1,3,4-Oxadiazol-2-ylbenzenesulfonamides as privileged structures for the inhibition of monoamine oxidase B
(Elsevier, 2019)The present study investigates the monoamine oxidase (MAO) inhibition properties of a series of ten 5-aryl-1,3,4-oxadiazol-2-ylbenzenesulfonamides. The target compounds were synthesized by dehydration of the corresponding ... -
2-Acetylphenol analogs as potent reversible monoamine oxidase inhibitors
(Dove Press, 2015)Based on a previous report that substituted 2-acetylphenols may be promising leads for the design of novel monoamine oxidase (MAO) inhibitors, a series of C5-substituted 2-acetylphenol analogs (15) and related compounds ... -
2-Benzylidene-1-indanone derivatives as inhibitors of monoamine oxidase
(Elsevier, 2016)In the present study, a series of twenty-two 2-benzylidene-1-indanone derivatives were synthesised and evaluated as inhibitors of recombinant human monoamine oxidase (MAO) A and B. The 2-benzylidene-1-indanone derivatives ... -
2-Heteroarylidene-1-indanone derivatives as inhibitors of monoamine oxidase
(Elsevier, 2016)In the present study a series of fifteen 2-heteroarylidene-1-indanone derivatives were synthesised and evaluated as inhibitors of recombinant human monoamine oxidase (MAO) A and B. These compounds are structurally related ... -
3-Coumaranone derivatives as inhibitors of monoamine oxidase
(Dove Press, 2015)The present study examines the monoamine oxidase (MAO) inhibitory properties of a series of 20 3-coumaranone [benzofuran-3(2H)-one] derivatives. The 3-coumaranone derivatives are structurally related to series of α-tetralone ... -
Azure B, a metabolite of methylene blue, is a high-potency, reversible inhibitor of monoamine oxidase
(Elsevier, 2012)Methylene blue (MB) has been shown to act at multiple cellular and molecular targets and as a result possesses diverse medical applications. Among these is a high potency reversible inhibition of monoamine oxidase A ... -
Benzyloxynitrostyrene analogues: a novel class of selective and highly potent inhibitors of monoamine oxidase B
(Elsevier, 2017)This study examines a series of novel 3-benzyloxy-β-nitrostyrene analogues as a novel class of inhibitors of the monoamine oxidase (MAO) enzymes. MAO inhibitors are considered useful for the treatment of depression and ... -
Caffeine as a lead compound for the design of therapeutic agents for the treatment of Parkinson’s disease
(Bentham Science, 2015)The current pharmacological therapies for the treatment of Parkinson’s disease are mostly inadequate and recent, improved therapeutic agents are required. Two important molecular targets for the design of anti-parkinsonian ... -
The design and evaluation of an l-dopa-lazabemide prodrug for the treatment of Parkinson’s disease
(MDPI, 2017)l-Dopa, the metabolic precursor of dopamine, is the treatment of choice for the symptomatic relief of the advanced stages of Parkinson’s disease. The oral bioavailability of l-dopa, however, is only about 10% to 30%, and ... -
Design, synthesis and evaluation of 3-hydroxypyridin-4-ones as inhibitors of catechol-O-methyltransferase
(Springer, 2020)The most effective treatment of Parkinson’s disease is restoring central dopamine levels with levodopa, the metabolic precursor of dopamine. However, due to extensive peripheral metabolism by aromatic L-amino acid decarboxylase ...